Technology area: Biotechnology & Pharmaceuticals
33 pending office actions • 30 art units • 32 examiners • 0 of 33 (0%) have an AI response strategy ready • 34 patents granted in the last 365 days
The Trustees of Dartmouth College has 33 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed among 32 examiners and 30 art units, indicating a broad prosecution footprint with only limited repeated assignment at the examiner level. The art-unit distribution is also wide, although it contains more concentration than the examiner distribution.
STOICA, ELLY GERALD is the busiest identified examiner, with 2 pending matters. Counsel may use that repeated assignment for focused review of examination practice, but the overall profile calls for centralized docket oversight, consistent support for claim amendments, and matter-specific analysis of technical and patentability issues.
Based on the USPTO statutory response window for each pending office action. 11 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 11 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (3%) |
| §101 + other | 1 (3%) |
| §103 only | 10 (30%) |
| §112 only | 6 (18%) |
| Double-patenting + other | 2 (6%) |
| Multi-statute (no §101) | 13 (39%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STOICA, ELLY GERALD | 2 | 66.8% | +22.6% |
| ALMO, KHAREEM E | 1 | 87.4% | +5.8% |
| CHOWDHURY, RAYEEZ R | 1 | 81.2% | +21.6% |
| CRANDALL, RICHARD W. | 1 | 29.9% | +34.2% |
| RAHMAN, MASUDUR | 1 | 72.9% | +31.7% |
| HODAC, ERIC KHOI | 1 | 85.5% | +12.8% |
| JUEDES, AMY E | 1 | 44.7% | +41.9% |
| MONTANARI, DAVID A | 1 | 64.8% | +49.0% |
| CHIN, CHRISTOPHER L | 1 | 80.7% | +22.4% |
| FAUST, AMBER KATHLEEN | 1 | 61.1% | +53.6% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18905400 | Engaging Multimodal Content Generation System | CHOWDHURY, RAYEEZ R | — |
| 18376380 | METHOD AND APPARATUS FOR ORDERED NANOPLASMONIC SENSOR FORMATION THROUGH MICROFLUIDIC ASSEMBLY | CHIN, CHRISTOPHER L | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18015627 | SYSTEMS AND METHODS FOR CELL CAPTURE, BIOMARKER DETECTION, AND CONTACT-FREE CELL LYSIS | LU, FRANK WEI MIN | 16d overdue |
| 18016109 | METHODS AND COMPOSITIONS FOR CRISPR/CAS9 GUIDE RNA EFFICIENCY AND SPECIFICITY AGAINST GENETICALLY DIVERSE HIV-1 ISOLATES | HUDSON, AMY ROSE | 5d |
| 18019757 | ACYCLIC/CYCLIC ETHER BASED ELECTROLYTES OUTSTRETCHING THE LOW TEMPERATURE LIMIT OF SODIUM METAL ANODE | AMPONSAH, OSEI K | 9d |
| 18749826 | Harmonic Radar Scanner for Electronics | HODAC, ERIC KHOI | 12d |
| 18901646 | Judicial Support Tool Computing System | CRANDALL, RICHARD W. | 49d |
| 17781406 | TARGETING MB2 OF THE MYC ONCOGENE AND ITS INTERACTION WITH TRRAP IN CANCER | SAMSELL, RILLA MARIE | 78d |
| 19182783 | SWITCHED-CAPACITOR GATE DRIVER FOR DRIVING CAPACITIVE LOADS | ALMO, KHAREEM E | — |
| 18795558 | NUCLEIC ACID CONSTRUCTS FOR CO-EXPRESSION OF CHIMERIC ANTIGEN RECEPTOR AND TRANSCRIPTION FACTOR, CELLS CONTAINING AND THERAPEUTIC USE THEREOF | RAHMAN, MASUDUR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18507469 | METHODS FOR TREATING CANCER USING T CELLS WHICH EXPRESS A CHIMERIC NK RECEPTOR | MONTANARI, DAVID A | 7d |
| 18749826 | Harmonic Radar Scanner for Electronics | HODAC, ERIC KHOI | 12d |
| 18901646 | Judicial Support Tool Computing System | CRANDALL, RICHARD W. | 49d |
| 18905400 | Engaging Multimodal Content Generation System | CHOWDHURY, RAYEEZ R | — |
| 18795558 | NUCLEIC ACID CONSTRUCTS FOR CO-EXPRESSION OF CHIMERIC ANTIGEN RECEPTOR AND TRANSCRIPTION FACTOR, CELLS CONTAINING AND THERAPEUTIC USE THEREOF | RAHMAN, MASUDUR | — |
| 18621312 | ANTI-NMDAR2B ANTIBODIES, ANTIBODY-DRUG CONJUGATES, AND CHIMERIC ANTIGEN RECEPTORS, AND COMPOSITIONS AND METHODS OF USE | JUEDES, AMY E | — |
| 18376380 | METHOD AND APPARATUS FOR ORDERED NANOPLASMONIC SENSOR FORMATION THROUGH MICROFLUIDIC ASSEMBLY | CHIN, CHRISTOPHER L | — |
| 18364503 | ENGINEERED NATURAL LIGAND-BASED CAR: DIRECTED EVOLUTION OF THE STRESS-RECEPTOR NKP30 | FAUST, AMBER KATHLEEN | — |
| Art Unit | Apps |
|---|---|
| 1644 | 2 |
| 1632 | 2 |
| 2836 | 1 |
| 2174 | 1 |
| 3619 | 1 |
| 1633 | 1 |
| 3648 | 1 |
| 1677 | 1 |
| 1643 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19182783 | SWITCHED-CAPACITOR GATE DRIVER FOR DRIVING CAPACITIVE LOADS | ALMO, KHAREEM E | 2836 | §102§103 | Non-Final OA | — | Pending | Apr 18, 2025 |
| 18905400 | Engaging Multimodal Content Generation System | CHOWDHURY, RAYEEZ R | 2174 | §103 | Non-Final OA | — | Pending | Oct 03, 2024 |
| 18901646 | Judicial Support Tool Computing System | CRANDALL, RICHARD W. | 3619 | §101 | Final Rejection | 49d | Pending | Sep 30, 2024 |
| 18795558 | NUCLEIC ACID CONSTRUCTS FOR CO-EXPRESSION OF CHIMERIC ANTIGEN RECEPTOR AND TRANSCRIPTION FACTOR, CELLS CONTAINING AND THERAPEUTIC USE THEREOF | RAHMAN, MASUDUR | 1633 | §102§112 | Non-Final OA | — | Pending | Aug 06, 2024 |
| 18749826 | Harmonic Radar Scanner for Electronics | HODAC, ERIC KHOI | 3648 | §102§103 | Non-Final OA | 12d | Pending | Jun 21, 2024 |
| 18621312 | ANTI-NMDAR2B ANTIBODIES, ANTIBODY-DRUG CONJUGATES, AND CHIMERIC ANTIGEN RECEPTORS, AND COMPOSITIONS AND METHODS OF USE | JUEDES, AMY E | 1644 | §112 | Non-Final OA | — | Pending | Mar 29, 2024 |
| 18507469 | METHODS FOR TREATING CANCER USING T CELLS WHICH EXPRESS A CHIMERIC NK RECEPTOR | MONTANARI, DAVID A | 1632 | §112 | Final Rejection | 7d | Pending | Nov 13, 2023 |
| 18376380 | METHOD AND APPARATUS FOR ORDERED NANOPLASMONIC SENSOR FORMATION THROUGH MICROFLUIDIC ASSEMBLY | CHIN, CHRISTOPHER L | 1677 | §112DP | Non-Final OA | — | Pending | Oct 03, 2023 |
| 18364503 | ENGINEERED NATURAL LIGAND-BASED CAR: DIRECTED EVOLUTION OF THE STRESS-RECEPTOR NKP30 | FAUST, AMBER KATHLEEN | 1643 | §102§103§112 | Non-Final OA | — | Pending | Aug 03, 2023 |
| 18359373 | IMMUNOSTIMULATORY CYTOKINE COMBINATION AND THERAPEUTIC USE THEREOF | CESARE, JOSEPH DAVID | 1675 | §102§103§112 | Non-Final OA | — | Pending | Jul 26, 2023 |
| 18222275 | DEVICE AND METHOD TO ASSIST REVISION SURGERIES FOR KNEE ARTHROPLASTY | RAMANA, ANURADHA | 3774 | §102§112 | Non-Final OA | — | Pending | Jul 14, 2023 |
| 18307522 | Methods of Treating Cystic Fibrosis | REDWOOD, CHRISTOPHER EVAN | 1629 | §103 | Non-Final OA | — | Pending | Apr 26, 2023 |
| 18295454 | CHIMERIC ANTIGEN RECEPTOR, REGULATORY CELLS AND METHODS OF USE | WEHBE, ANNE MARIE SABRINA | 1634 | §112 | Final Rejection | — | Pending | Apr 04, 2023 |
| 17790245 | METAL PHOSPHOROTHIOATES AND METAL-SULFUR ELECTROCHEMICAL SYSTEM CONTAINING THE SAME | CHOI, EVERETT TIMOTHY | 1751 | §103 | Non-Final OA | — | Pending | Jun 30, 2022 |
| 17782252 | ADOPTIVE CELL THERAPY WITH ZBTB20 SUPPRESSION | MATALKAH, FATIMAH KHALAF | 1638 | §112 | Final Rejection | — | Pending | Jun 03, 2022 |
| 17781406 | TARGETING MB2 OF THE MYC ONCOGENE AND ITS INTERACTION WITH TRRAP IN CANCER | SAMSELL, RILLA MARIE | 1624 | §102§112 | Final Rejection | 78d | Pending | Jun 01, 2022 |
| 19058657 | MONOLITHIC THREE-DIMENSIONAL NEURAL PROBES | KIM, EUN HWA | 3794 | §102§103§112 | Non-Final OA | — | Pending | Feb 20, 2025 |
| 18784881 | INTEGRATED BIOMATERIAL SCAFFOLD WITH 3D PRINTED LATTICE BACKBONE | TRUONG, QUANGLONG N | 1615 | §103 | Non-Final OA | — | Pending | Jul 25, 2024 |
| 18729821 | SYSTEMS AND METHODS FOR DETERRING VIRAL TRANSMISSION USING NEURAL NETWORKS | BARR, MARY EVANGELINE | 3682 | §101§103 | Non-Final OA | — | Pending | Jul 17, 2024 |
| 18703610 | NEOADJUVANT USAGE OF PLANT VIRUS OR VIRUS-LIKE PARTICLES FOR CANCER TREATMENT | FOLEY, SHANON A | 1671 | §103 | Non-Final OA | — | Pending | Apr 22, 2024 |
| 18599832 | METHOD FOR ATTENUATING NEUROINFLAMMATION, AMYLOIDOPATHY AND TAUOPATHY | COUGHLIN, MATTHEW P | 1626 | §103§112DP | Final Rejection | — | Pending | Mar 08, 2024 |
| 18685671 | FUNCTIONALIZATION OF MICROSCALE 3D-PRINTED POLYMER STRUCTURES WITH NANOSCALE VAPOR DEPOSITED ELECTRONIC LAYERS | ROBINSON, MICHAEL | 1787 | §103§112 | Non-Final OA | — | Pending | Feb 22, 2024 |
| 18578900 | FLEXIBLE PIEZOELECTRIC ARRAY FOR WEARABLE BLOOD PRESSURE SENSING | EPPERT, LUCY CLARE | 3791 | §103 | Non-Final OA | 31d overdue | Pending | Jan 12, 2024 |
| 18578674 | MULTIFUNCTIONAL HOLLOW SILICA NANOFIBER EXTRACELLULAR MATRIX | GIERE, REBECCA M | — | §102§103§112 | Non-Final OA | — | Pending | Jan 11, 2024 |
| 18514761 | ENGINEERED NEMO AND USES THEREOF | STOICA, ELLY GERALD | 1647 | §112 | Non-Final OA | — | Pending | Nov 20, 2023 |
| 18560179 | LIVER X RECEPTOR MODULATORS | KENYON, JOHN S | 1625 | §112 | Non-Final OA | — | Pending | Nov 10, 2023 |
| 18263471 | METHODS FOR INCREASING VIRAL TRANSDUCTION OF CELLS | TAKENAKA, RISA | 1632 | §103 | Final Rejection | 13d | Pending | Jul 28, 2023 |
| 18260741 | OVARIAN CANCER VACCINE | STOICA, ELLY GERALD | 1644 | §103 | Final Rejection | — | Pending | Jul 07, 2023 |
| 18209941 | Localizing Underwater Robots from the Air | MOORE, WHITNEY | 3646 | §103 | Final Rejection | 118d overdue | Pending | Jun 14, 2023 |
| 18019757 | ACYCLIC/CYCLIC ETHER BASED ELECTROLYTES OUTSTRETCHING THE LOW TEMPERATURE LIMIT OF SODIUM METAL ANODE | AMPONSAH, OSEI K | 1752 | §102§103 | Non-Final OA | 9d | Pending | Feb 03, 2023 |
| 18016109 | METHODS AND COMPOSITIONS FOR CRISPR/CAS9 GUIDE RNA EFFICIENCY AND SPECIFICITY AGAINST GENETICALLY DIVERSE HIV-1 ISOLATES | HUDSON, AMY ROSE | 1636 | §102§103 | Non-Final OA | 5d | Pending | Jan 13, 2023 |
| 18015627 | SYSTEMS AND METHODS FOR CELL CAPTURE, BIOMARKER DETECTION, AND CONTACT-FREE CELL LYSIS | LU, FRANK WEI MIN | 1683 | §102§103 | Final Rejection | 16d overdue | Pending | Jan 11, 2023 |
| 16289118 | Method for Enhancing Red Blood Cell Quality and Survival During Storage | MARTIN, PAUL C | 1653 | §103 | Final Rejection | 75d | Pending | Feb 28, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe Trustees of Dartmouth College has 33 pending office actions as of October 2026, spread across 30 art units and 32 examiners.
Elly Gerald Stoica has the most, with 2 of The Trustees of Dartmouth College's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
